## ALIMERA SCIENCES, INC.

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

to EyePoint Parent for years 2025 to 2028 is included in the cost of the intangible the Company recorded. The estimated royalties will continue to be revalued at each reporting date until they are settled.

Concurrently in May 2023, the Company also entered into a commercial supply Agreement") with EyePoint Parent pursuant to which, during the term of the Agreement, EyePoint Parent will be responsible for manufacturing and exclusively supplying (subject to certain exceptions) to agreed-upon quantities of YUTIQ necessary for the U.S. at certain cost-plus anounts, subject to adjustments. EyePoint Parent's manufacture and supply of YUTIQ will be exain exceptions) until the Company has the ability to manufacture and supply YUTIQ for commercialization in the Supply Arreement is for a period of two vears through May 2025 and thereafler automatically renews for successive one-vear terms unless either party provides notice of non-renewal to the other party within a specified period of time prior to the next automatic renewal term. provided that the Supply Agreement automatically terminates upon the transfer of manufacturing for YUTQ to the Company or its designee. The Supply Agreement also automatically termination of the Product Rights Agreement.

The Company's license rights to EyePoint's proprietary device could revert to EyePoint if the Company were to: (i) fail twice to cure its breach of an obligation to make certain payments to EyePoint following receipt of witten notice thereof; (ii) fail to cure other breaches of material terms of the EyePoint Agreement within 30 days after notice of such longer period (up to 90 days) as may be reasonably necessary if the breach cannot be cured within such 30-day period; (iii) file for protection under the bankruptcy laws, make an assigment for the benefit of creditors, appoint or suffer appointment of a receiver or trustee over its property, file a petition under act or have any such petition filed against it and such proceeding remains undismissed or unstayed for a period of more than 60 days; or (iv) notify EyePoint in writing of its decision to abandon its license with respect to a certain product using EyePoint's proprietary insert technology.

## Ocumension License Agreement

On April 14, 2021, the Company entered into an exclusive license Agreement") with Ocumension (Hong Kong) Limited ("Ocumension HK"), a wholy owned subsidiary of Ocument and commercialization under Ocumension HK's own brand name(s), either directly or through its affliates or approved third-party s 190 microgram fluccinolone acetonide intravitreal implant in applicator (the "Product," currently marketed in the United States, Europe, and the Middle East as ILUVIEN) for the treatment and prevention of eye diseases in humans, other than weitis, in a specified territory. The Territory is defined of China, including Hong Kong SAR and Macau SAR, region of Taiwan, South Korea, Brunei, Cast Timor, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam,

The Company received a nonrefundable upfront of \$10.0 million from Ocumension HK and may in the future receive additional salesbased milestone payments totaling upon the achievements by Ocumension HK of certain specified sales milestones during the term of the License Agreement of the Company's receipt of fulure milestone payments depends upon whether Ocumension HK is able to successfully complete product and commercialization in the Territory, which requires, among other things, obtaining necessary requlatory approvals and appropriate reimbursement priscipling in the Territory, a process that may take several vears. In 2021, the Company recognized \$1,0 million in license revenue from the value of a warrant subscription agreement, which the Company received as consideration, to purchase 1,000.000 shares of Ocumension during a period of four years). As of December 31, 2023 and 2022, the Company has approximately \$0.4 million respectively, of deferred revenue under the Ocumension license agreement that will be recognized over the remaining term of the agreement once Ocumension begins to sell the overed products under the license agreement.

The term of the License will continue (a) until the 10th anniversal sale of the Product in any country of urisdiction in the Territory or (b) for as long as Ocumercializing the Product in any part of the Territory, whichever is later. The term is subject to the Company's right to partially terminate the Agreement beginning on the 10th anniversary of the effective date with respect to any country or jurisdiction in the Territory in which Ocumension hist commercial sale and is not continuing to commercialize the Product. Ocumension will purchase Product from the Company at a fixed transfer price without revally obligation on future sale (other than miles)one payments as described above). Ocumension HK is responsible for all costs of development and commercialization in the Territory.

## Ocumension Share Purchase Agreement

When the Company entered into the license agreement in April 2021, it also entered into a share purchase agreement ("Share Purchase Agreement") with Ocumension, pursuant to which the Company offered and sold to Ocumension 1,144,945 shares of common stock at a purchase price of \$8.734044 per share and aggregate gross proceeds of \$10.0 million from the sale of the shares.

77